<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7280142\results\search\testTrace\results.xml">
  <result pre="70 000 lives (by April 7, 2020). As the viral" exact="infection" post="is driven by increased angiotensin-converting enzyme-2 (ACE2) expression, with"/>
  <result pre="severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may receive complimentary" exact="treatment" post="modalities to enhance therapeutic response. Take Home Message This"/>
  <result pre="of renal cell carcinoma patients diagnosed with COVID-19. Keywords Viral" exact="infection" post="Renal tumors Therapeutic targeting Associate Editor: Malte Rieken 1"/>
  <result pre="lead to acute respiratory distress syndrome (ARDS) or pneumonia. However," exact="diagnosis" post="is often complicated by a large portion of patients"/>
  <result pre="association with certain comorbidities, and potential therapeutic strategies for the" exact="treatment" post="of COVID-19. As millions of cancer patients are fighting"/>
  <result pre="current understanding of the impact of angiotensin-converting enzyme-2 (ACE2)-mediated SARS-CoV-2" exact="infection" post="on kidney function and the therapeutic targeting of underlying"/>
  <result pre="chronic renal disease. 3 Evidence synthesis 3.1 Mechanisms of SARS-CoV-2" exact="infection" post="The novel zoonotic coronavirus (CoV) SARS-CoV-2 belongs to the"/>
  <result pre="the Î²-coronaviruses batâ€�SLâ€�CoV ZC45 and batâ€�SLâ€�CoV ZXC2, and can cause" exact="infection" post="of lower respiratory track and pneumonia in humans. Fig."/>
  <result pre="for four structural proteins that are functionally involved in the" exact="infection" post="process. The four structural proteins include the membrane (M),"/>
  <result pre="cell and is regulated by androgens (Fig. 2 ). SARS-CoV" exact="infection" post="is dependent on the proteolytic activity of TMPRSS2 and"/>
  <result pre="making these organ sites easy routes for SARS-CoV and SARS-CoV-2" exact="infection" post="[23]. In particular, ACE2 expression is higher in the"/>
  <result pre="physicians about for whom, how, and when to provide cancer" exact="treatment" post="and follow-up care [27]. However, delays in cancer management"/>
  <result pre="in cancer management might lead to missed opportunities for curative" exact="treatment" post="and increased risks of cancer progression to metastasis, anxiety,"/>
  <result pre="hospital-based palliative care and symptom management [27]. For patients receiving" exact="treatment" post="with chemotherapy or immunotherapy, or those who have undergone"/>
  <result pre="emotional well-being in a population already burdened by cancer and" exact="treatment" post="impact. To address some of these needs, several hospitals"/>
  <result pre="patients participating in cancer clinical trials, forced stay home or" exact="quarantine" post="complicates hospital attendance for repeat appointments and continuity in"/>
  <result pre="continuity in care, and when severe complications or emergencies occur," exact="treatment" post="delays or unavailability will have significant implication for the"/>
  <result pre="Surgical management of RCC amid COVID-19 The goal of surgical" exact="treatment" post="for RCC is twofold: the first is the removal"/>
  <result pre="pandemic has transformed the way we are approaching the surgical" exact="treatment" post="of kidney cancer. The recommendations to be followed to"/>
  <result pre="progression must be weighed against the risks of COVID-19. COVID-19" exact="testing" post="All patients planning to undergo surgery for kidney cancer"/>
  <result pre="[36]. In the USA specifically, 0.5 million individuals receive dialysis" exact="treatment" post="and constitute a high-risk group for adult respiratory distress"/>
  <result pre="infected with the virus (Fig. 3 ). Fig. 3 SARS-CoV-2" exact="infection" post="in renal disease and therapeutic targeting of RCC. The"/>
  <result pre="shows an overview of the primary signaling targets of viral" exact="infection" post="and their association with renal disease. The bottom panel"/>
  <result pre="of the vascular endothelial growth factor receptor (VEGFR) [47]. Antiangiogenesis" exact="treatment" post="of RCC includes the use of monoclonal antibodies that"/>
  <result pre="sunitinib and paxopanib, were first to be approved for frontline" exact="treatment" post="of metastatic RCC (mRCC) [48]. The use of immune"/>
  <result pre="immune checkpoint inhibitors (ICIs) has become increasingly popular in the" exact="treatment" post="of RCC. ICIs work to prevent the downregulation of"/>
  <result pre="axitinib [53]. The efficacy of ICIs in conjugation with COVID-19" exact="infection" post="is under intense investigation. Recent evidence suggests that restoration"/>
  <result pre="treating COVID-19 [34]. This is of particular significance in the" exact="treatment" post="of RCC patients with COVID-19 infection, as the treatment"/>
  <result pre="the treatment of RCC patients with COVID-19 infection, as the" exact="treatment" post="of ICIs and tocilizumab may overcome irAE side effects."/>
  <result pre="use of ACEis in RCC has significant implications in the" exact="treatment" post="of RCC patients who are infected with COVID-19 (Fig."/>
  <result pre="antagonists Endothelin receptor antagonists (ERAs) have been developed for the" exact="treatment" post="of various cancers including renal cancer. The drugs decrease"/>
  <result pre="ERAs have been shown to be promising agents in the" exact="treatment" post="of chronic kidney disease as well [62]. Consequential to"/>
  <result pre="affects portal arterial hypertension (PAH), and ERAs are a common" exact="treatment" post="against PAH by reducing the vasoconstrictive effects of ET-1"/>
  <result pre="with hypertension to defend themselves against COVID-19. 3.6 Stratification and" exact="screening" post="COVID-19 patients using liquid biopsy â€œLiquid biopsyâ€� is a"/>
  <result pre="and approved by the US FDA for the prognosis and" exact="diagnosis" post="of the disease [70]. RCC-associated tumor-based CTCs and cfDNA"/>
  <result pre="viral RNA copies are present in blood (current tool of" exact="diagnosis" post="is a nasopharyngeal swab followed by a reverse transcriptase"/>
  <result pre="patients [8]. This evidence supports that liquid biopsyâ€&quot;assisted stratification and" exact="screening" post="of COVID-19 patients with pre-existing RCC must focus on"/>
  <result pre="For several of the patients with renal disease and AKI," exact="treatment" post="course proceeds similarly to that of most COVID-19 cases,"/>
  <result pre="of viremia [34], [74]. Additional therapeutic options effective in the" exact="treatment" post="of COVID-19 patients are discussed below [75]. 3.7.1 Monoclonal"/>
  <result pre="The development of neutralizing antibodies poses an issue in rapid" exact="treatment" post="strategy, as traditional screen options may be too slow"/>
  <result pre="too slow for the pandemic to ensure sufficient breadth of" exact="treatment" post="[75]. 3.7.2 Oligonucleotides Targeting the SARS-CoV-2 viral RNA genome"/>
  <result pre="Commission recommends interferon-Î± and lopinavir/ritonavir, HIV protease inhibitors, in the" exact="treatment" post="of COVID-19, as these treatments have had some clinical"/>
  <result pre="treating MERS in mouse models and was effective in the" exact="treatment" post="of a COVID-19 patient in the USA [75], [78]."/>
  <result pre="in Wuhan, ChinaJAMA323202010611069 26CDC COVID-19 Response TeamPreliminary estimates of the" exact="prevalence" post="of selected underlying health conditions among patients with coronavirus"/>
  <result pre="Med38220202012202232227758 33Wang L, Li X, Chen H, et al. SARS-CoV-2" exact="infection" post="does not significantly cause acute renal injury: an analysis"/>
  <result pre="Cancer82020e000319 51EscudierB.PortaC.SchmidingerM.Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis," exact="treatment" post="and follow-upAnn Oncol272016v586827664262 52AlbigesL.PowlesT.StaehlerM.Updated European Association of Urology guidelines"/>
  <result pre="carcinoma: immune checkpoint inhibition is the new backbone in first-line" exact="treatment" post="of metastatic clear-cell renal cell carcinomaEur Urol76201915115631151678 53RassyE.FlippotR.AlbigesL.Tyrosine kinase"/>
  <result pre="cell carcinomaTher Adv Med Oncol122018113 54BersanelliM.Controversies about COVID-19 and anticancer" exact="treatment" post="with immune checkpoint inhibitorsImmunotherapy12202026927332212881 55SobczukP.SzczylikC.PortaC.CzarneckaA.M.Renin angiotensin system deregulation as"/>
  <result pre="coronavirus infectionAnn Intern Med160201438939724474051 74RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet395202047347532043983 75KruseR.L.Therapeutic strategies in an outbreak"/>
  <result pre="synthetic peptide epitope-CpG-DNA-liposome complexBMB Rep52201939740230355437 77ChuC.M.ChengV.C.C.HungI.F.N.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: Initial virological and clinical findingsThorax59200425225614985565 78HolshueM.L.DeBoltC.LindquistS.First case"/>
 </snippets>
</snippetsTree>
